• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Glenn Dranoff, MD

Professor, Department of Medicine, Harvard Medical School

Director, Human Gene Transfer Laboratory Core, Dana-Farber Cancer Institute

Co Leader, Cancer Vaccine Center, Medical Oncology, Dana-Farber Cancer Institute

Contact Info

Glenn Dranoff
Dana-Farber Cancer Institute
450 Brookline Avenue
Boston, MA, 02215
Mailstop: Dana 520C
Phone: 617-632-5051
Fax: 617-632-5167
glenn_dranoff@dfci.harvard.edu

Assistant

Not Available.

DF/HCC Program Affiliation

Leukemia
Cancer Immunology, Leader
Cutaneous Oncology and Melanoma
Lymphoma and Myeloma

DF/HCC Associations

Member, Center Scientific Council

Research Abstract

We have demonstrated that vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony stimulating factor (GM-CSF) generates potent, specific, and long-lasting anti-tumor immunity in multiple murine tumor model systems. Vaccination requires the participation of both CD4 and CD8 positive lymphocytes and likely involves augmenting the function of professional antigen presenting cells, such as macrophages and dendritic cells. To test whether this approach will also augment anti-tumor immunity in patients with cancer, we have conducted several Phase I clinical trials of vaccination with lethally irradiated, autologous tumor cells engineered to secrete human GM-CSF in patients with advanced melanoma, non-small cell lung carcinoma, or myeloid leukemia. These studies have shown the diffuse infiltration of pre-existing tumor masses following vaccination with large numbers of CD4 and CD8 positive T lymphocytes and plasma cells. The targeted destruction of tumor blood vessels by lymphocytes, eosinophils, and neutrophils has also been observed. We are currently cloning the antigens which are the targets of T and B cell immune responses in vaccinated patients.

We have also generated mice lacking GM-CSF, interleukin-3, and interferon-gamma by gene targeting techniques in embryonic stem cells. Remarkably, these mice spontaneously develop at high frequency diverse hematologic and solid neoplasms within a background of chronic inflammation and infection. The mechanisms underlying tumor formation are under active study.

Publications

View All Publications